Author Manuscript Published OnlineFirst on January 9, 2012; DOI: 10.1158/0008-5472. CAN-11-2950 Malignancies of the exocrine pancreas are the fourth most common cause of cancer death in the U.S., with an estimated 44,000 new cases and 38,000 deaths in 2011 (1) We examined whether circulating DBP, the major vitamin D transport protein, is associated with pancreatic cancer risk both overall and relative to 25(OH)D concentration, and whether it modifies the association between higher 25(OH)D status and elevated pancreatic cancer risk.
Participants and Methods

Study population
The overall design, rationale, and objectives of the ATBC Study have been previously published (8) . From 1985 From to 1988 , the ATBC Study recruited 29,133 Finnish male smokers between the ages of 50 and 69 years to participate in a controlled primary prevention trial. Daily supplementation with α-tocopherol (50 mg dl-α-tocopheryl acetate/day), β-carotene (20 mg/day), both, or placebo continued for [5] [6] [7] [8] years (median 6.1 years) until death or trial closure (April, 1993) (8) . Participants were followed-up passively during the post-intervention period through linkage with the Finnish Cancer Registry, which provides nearly 100% case ascertainment (9) . The study was approved by the institutional review boards of the U.S. National Cancer Institute and the National Public Health Institute of Finland, and written informed consent was obtained from each participant.
Case identification and control selection
Subjects for the present study were drawn from two existing ATBC nested case/control sub-studies, both of which included prior measurement of 25(OH)D. All case/control matched pairs with available residual serum were selected for DBP assay. (RIA) or 5% (CLIA) blinded quality control samples. Samples from the same quality control pool were included in both sets of assays, with a median of 47.9 nmol/L (n=30 samples) using RIA and 53.0 nmol/L (n=154) using CLIA. In addition, 17 controls were included in both sub-studies and all but one was higher using the RIA compared with the CLIA, with a mean difference of 13.1 nmol/L between the two measurements.
Coefficients of variation were 16.5% overall for the RIA (5.5% interbatch and 15.5% intrabatch) and 12.3% overall for the CLIA (7.1% interbatch and 10.1% intrabatch).
Intraclass correlations were 86.7% and 96.0% for the RIA and CLIA, respectively. Author Manuscript Published OnlineFirst on January 9, 2012; DOI: 10.1158/0008-5472. CAN-11-2950 among controls. Odds ratios (OR) and 95% confidence intervals (CI) were determined using conditional logistic regression models. Because the unconditional logistic regression results were similar, this approach was used for stratified modeling in order to retain subjects who were not in the same stratum as their matched case or control.
Both 25(OH)D and DBP were categorized as quartiles based on the distribution among the controls and entered into the models as indicator variables. Quartiles rather than quintiles were used for greater stability in estimation of the odds ratios, especially for stratified models, but findings for quintiles were similar. Because of the slight differences in the 25(OH)D data from the two laboratories, and because 25(OH)D levels are known to fluctuate throughout the year, the 25(OH)D quartiles are calculated separately for each laboratory by sunnier and less sunny season categories (MayOctober and November-April) and then merged into one quartile variable. Results were essentially unchanged when 25(OH)D was instead categorized using clinically defined cutpoints or adjusted for season using the residual method (11) . Exclusion of participants reporting a history of diabetes did not materially change the risk estimates, therefore, these subjects were retained.
A molar ratio of 25(OH)D:DBP was created as a proxy for free circulating 25(OH)D (12, 13) . In addition, we estimated "free 25(OH)D" based on total 25(OH)D and DBP using the affinity constants of albumin and DBP (12, 14) both by ignoring albumin (based on its relatively smaller vitamin D transport function) and by assigning a fixed albumin value to every subject (because of limited biospecimen availability, we did not measure albumin). As described previously (12) Author Manuscript Published OnlineFirst on January 9, 2012; DOI: 10.1158/0008-5472. CAN-11-2950 ratio. We also adjusted 25(OH)D for DBP through the residual method used to adjust for season (11) . Tests for linear trend were obtained by assigning to each category an ordinal value (1-4) and treating this parameter as a continuous variable. DBP was also modeled as a continuous variable of 1000 nmol/L increments.
Variables assessed for confounding included those identified in previous publications (3, 4) and those associated with DBP as identified in Table 1 Additional testing of several medical history variables (history of renal failure, pancreatitis, liver cirrhosis, lung emphysema, chronic bronchitis, stroke, cerebral hemorrhage, cerebral infarction, valvular heart disease, myocardial infarction, coronary heart disease, angina pectoris, or heart failure) did not alter the DBP results.
To evaluate effect modification, we stratified DBP by 25(OH)D, and 25(OH)D and the ratio of 25(OH)D:DBP by DBP. We also examined DBP stratified by age, BMI, number of cigarettes/day, occupational physical activity, season of blood collection, intakes of fat (total, monounsaturated, saturated, and trans fat), folate, vitamin D, calcium, and ethanol, and follow-up time. Effect modification was tested by including the cross-product term of the biomarker quartiles and the effect modifier (split at the median or yes/no), and by stratified analyses conducted using unconditional logistic regression, adjusted for the matching factors only. Statistical analyses were performed using SAS software version 9.1.3 (SAS Institute, Inc., Cary, North Carolina) and all Pvalue were 2-sided. The inverse association between DBP and pancreatic cancer was stronger among older men, those with lower intakes of fat (all types examined), vitamin D, calcium, and ethanol, those who smoked less, and for cases with at least 10 years between blood collection at study entry and diagnosis (data not shown). None of the interaction tests for these factors were significant, however. (6, 21) , and less than 5% of circulating DBP is associated with vitamin D compounds (19, 20) . The large excess of DBP compared to vitamin D provides a reservoir for 25(OH)D, prolongs its half-life and protects against short-term vitamin D deficiency; it may also relate to other functions of DBP that are described below (5, 20) . Circulating DBP concentrations show some diurnal variation with a morning nadir and rapid daytime increase in levels, but in contrast to vitamin D levels, they do not vary by season (13, 22) . Fatty acids also bind to DBP, thereby reducing its capacity for vitamin D compounds (5,6); of note in this regard, the inverse pancreatic cancer association for DBP was marginally stronger among those with lower fat intake in our study.
Results
Serum
Discussion
In addition to its role in vitamin D transport, DBP functions as an actin scavenger, as a precursor to a macrophage activating factor, and as a cochemotactic factor (5, 6, 23, 24) . Actin is released into circulation following cellular injury or death, and can result in platelet aggregation, vascular obstruction, and organ dysfunction. By binding actin, DBP attenuates these effects (5,6), which may be one reason for very high DBP concentrations compared with vitamin D (5). The DBP-macrophage activating factor, a selectively deglycosylated form of DBP, has anti-angiogenic, anti-tumorigenic, immunemodulatory, and pro-apoptotic properties (5, 25, 26) , and has been shown to inhibit pancreatic (25) and prostate tumor growth (26) . DBP also plays a role in inflammation, acting as a co-chemotactic factor by attracting neutrophils to sites of inflammation through its influence on complement-derived peptides (C5a) (5, 6, 24) . 
